LENZ Therapeutics (NASDAQ:LENZ) Coverage Initiated at William Blair

William Blair began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a report issued on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating on the stock. William Blair also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.74) EPS, Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.44) EPS, FY2024 earnings at ($2.10) EPS and FY2025 earnings at ($2.95) EPS.

LENZ has been the topic of a number of other reports. Piper Sandler initiated coverage on shares of LENZ Therapeutics in a report on Wednesday, March 27th. They issued an overweight rating and a $28.00 price objective on the stock. Citigroup initiated coverage on shares of LENZ Therapeutics in a research report on Wednesday, April 10th. They set a buy rating and a $34.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, LENZ Therapeutics has a consensus rating of Buy and an average price target of $31.33.

LENZ Therapeutics Trading Down 11.1 %

Shares of LENZ Therapeutics stock opened at $17.70 on Monday. The company has a market capitalization of $147.30 million, a P/E ratio of -1.13 and a beta of 0.20. LENZ Therapeutics has a 52-week low of $14.07 and a 52-week high of $29.82.

Insiders Place Their Bets

In other news, Director Ra Capital Management, L.P. acquired 998,009 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was bought at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the transaction, the director now directly owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 38.40% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.